Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Other financing activities (2021 - 2026)

Longeveron (LGVN) posted quarterly Other financing activities of $1.3 million for Q1 2026, down 85.0% quarter-over-quarter from $8.5 million in Q2 2025.

Longeveron (LGVN) Other financing activities (2021 - 2026) Analysis & Trends

Longeveron's Other financing activities history runs 4 years deep, the most recent figure standing at $1.3 million for Q1 2026.

  • In Q1 2026, Other financing activities changed N/A year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $9.8 million (up 146.94% YoY), while the FY2024 annual figure was $16.2 million, up 16421.43% from the prior year.
  • Other financing activities for Q1 2026 stood at $1.3 million, down from $8.5 million in the prior quarter.
  • The five-year high for Other financing activities was $8.5 million in Q2 2025, with the low at $3000.0 in Q4 2024.
  • The 3-year median for Other financing activities is $3.6 million (2024), against an average of $3.9 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 87,000.00
Jun 30, 2026 87,000.00
Mar 31, 2026 1.28 Mn
Mar 31, 2026 1.28 Mn
Jun 30, 2025 8.50 Mn
Jun 30, 2025 8.50 Mn
Dec 31, 2024 3,000.00
Dec 31, 2024 3,000.00
Sep 30, 2024 5.85 Mn
Sep 30, 2024 5.85 Mn
Dec 31, 2021 -26.69 Mn
Dec 31, 2021 -26.69 Mn
Jun 30, 2021 24.20 Mn
Jun 30, 2021 24.20 Mn